MOTS-c vs NAD+ at AgeDefy Peptide

NAD+ vs MOTS-c: which is better?

For evidence from human intervention trials, oral NAD+ precursors have the advantage. NMN has a controlled finding in muscle insulin sensitivity, and NMN and NR have demonstrated blood NAD+ elevation. The 2025 review still describes limited clinical efficacy overall. A higher blood measurement establishes a molecular response; the larger question about sustained human function remains unsettled.

For muscle preservation during disuse, MOTS-c has a particularly interesting preclinical CK2 and atrophy investigation. The relevant experiments used mice and cell-free assays. There are no completed human efficacy trials of administered MOTS-c in this record.

My preference as a reader is for the question about function to come first. The current evidence supports neither molecule as the better way to preserve human muscle, and neither has established human longevity benefits.

Molecule and mechanism

The mechanism descriptions come from the NAD+ metabolism review, the MOTS-c review and the CK2 experiments. The comparison concerns two different molecular roles. NAD+ participates in energy reactions and supplies enzymes that consume it; MOTS-c acts as a peptide signal. The name “NAD peptide” sometimes groups them together in searches, but NAD+ is a coenzyme.

Human muscle and mouse performance

The NMN trial involved prediabetic, postmenopausal women. Muscle insulin sensitivity improved while body composition and HbA1c stayed unchanged. The MOTS-c performance experiments involved aged mice tested for running capacity, grip strength and gait. Those outcomes cannot be ranked against the human metabolic result as if both papers ran the same test.

The MOTS-c dialysis cohort adds a third type of evidence: a relationship between naturally circulating peptide and a combined mortality/cardiovascular endpoint. It asks about risk prediction in chronic hemodialysis patients. The study provides no test of administering MOTS-c.

The study I’m waiting for would measure muscle function over time in people. Until then, selecting a winner would conceal the very differences that make the research worth comparing.

Oral precursors and infusions

Most controlled NAD+ human evidence here comes from oral precursors: NMN and NR. Those studies cannot be used interchangeably with an NAD+ infusion claim. The current record describes minimal controlled evidence for intravenous NAD+, infusion-related discomfort and contamination risks for compounded preparations.

The MOTS-c experiments used research administration in animals or cell-based and cell-free systems. Its human half-life, dose-response and efficacy remain unestablished. A comparison of these routes is useful precisely because the names alone leave so much out.

Approval, anti-doping and safety

NAD+ is not an approved drug, and compounded injectable NAD+ has no FDA approval. Its precursors have been sold as dietary supplements; FDA has contested the supplement status of NMN. NAD+ and its precursors are not WADA-prohibited in the current account.

MOTS-c has no FDA approval, including in compounded prescription preparations, and it is prohibited in governed sport. Research-labelled supply and patient-specific prescription preparation are distinct contexts. A clinical assessment does not supply the missing human efficacy or long-term safety results.

The unresolved safety questions differ. NAD+ raises route-specific infusion and contamination concerns, short trial durations and a theoretical concern about existing cancers. MOTS-c has the more basic problem of an unestablished human side-effect and pharmacokinetic profile. The FAQ addresses the practical questions without turning animal findings into a human plan.